Treatment of Haemophilus influenzae Infection
For H. influenzae infections, use ceftriaxone (50-100 mg/kg/day every 12-24 hours) or cefotaxime (150 mg/kg/day every 8 hours) as first-line parenteral therapy, and amoxicillin-clavulanate (amoxicillin component 45-90 mg/kg/day) for oral therapy, given the high prevalence of β-lactamase-producing strains. 1
Treatment Algorithm by Clinical Severity
Severe/Hospitalized Cases (Pneumonia, Meningitis, Bacteremia)
Parenteral therapy is mandatory:
- First-line: Ceftriaxone (50-100 mg/kg/day IV every 12-24 hours) or cefotaxime (150 mg/kg/day IV every 8 hours) 1
- Alternative (if β-lactamase negative confirmed): Ampicillin 150-200 mg/kg/day IV every 6 hours 1
- Fluoroquinolone alternatives: IV ciprofloxacin (30 mg/kg/day every 12 hours) or IV levofloxacin (16-20 mg/kg/day every 12 hours for ages 6 months-5 years; 8-10 mg/kg/day once daily for ages 5-16 years; max 750 mg) 1
The guideline prioritizes third-generation cephalosporins because they maintain activity regardless of β-lactamase production 1. This is critical since recent data from France shows resistance rates to amoxicillin at 61.4% and to amoxicillin-clavulanate at 47.4%, with cefotaxime resistance at 39.3% 2. Despite this concerning resistance pattern, cefotaxime remains effective against 78.8% of extensively drug-resistant strains 3.
Mild-Moderate/Outpatient Cases
Oral step-down or initial therapy:
- First-line: Amoxicillin-clavulanate (amoxicillin component 45 mg/kg/day in 3 doses OR 90 mg/kg/day in 2 doses) if β-lactamase producing 1
- If β-lactamase negative (rare): Amoxicillin alone (75-100 mg/kg/day in 3 doses) 1
- Alternatives: Cefdinir, cefixime, cefpodoxime, or ceftibuten 1
Special Consideration: Influenza Superinfection
For bacterial superinfection complicating influenza, empiric coverage must include H. influenzae along with S. pneumoniae and S. aureus. Use amoxicillin-clavulanate, cefpodoxime, cefprozil, cefuroxime, or a respiratory fluoroquinolone 4.
Critical Decision Points
β-Lactamase Testing
While guidelines differentiate treatment based on β-lactamase production 1, in practice, assume β-lactamase production and treat accordingly given that 61-78% of strains produce β-lactamase in contemporary surveillance 2, 5. Testing should guide de-escalation, not initial therapy.
When to Avoid Ampicillin
Never use ampicillin empirically without susceptibility confirmation. The CDC estimates 18-22% ampicillin resistance nationally, but this varies significantly by region 6. Patients who are acutely ill, fail ampicillin therapy, or have laboratory-confirmed ampicillin resistance require alternative agents 6.
Benzylpenicillin Controversy
Despite Scandinavian recommendations for benzylpenicillin in community-acquired pneumonia, recent data shows lower early clinical response rates compared to wide-spectrum β-lactams (81% vs 84%, p=0.011) for H. influenzae infections, though mortality differences were not statistically significant 7. Avoid benzylpenicillin for confirmed H. influenzae infections—use agents with established activity.
Common Pitfalls
Amoxicillin monotherapy: The 61.4% resistance rate makes first-line amoxicillin use questionable even for mild infections 2. Always use amoxicillin-clavulanate unless β-lactamase negativity is confirmed.
Low sputum penetration: Amoxicillin-clavulanate achieves surprisingly low sputum levels (0.05-0.54 mcg/mL), which may explain the 22% relapse rate with H. influenzae respiratory infections 5. Consider this when treating lower respiratory tract infections.
Blood culture as risk marker: Blood culture positivity is an independent risk factor (OR 4.069) for extensively drug-resistant H. influenzae 3. These patients warrant broader-spectrum therapy and closer monitoring.
High-Risk Populations Requiring Aggressive Treatment
- Immunodeficiency states
- Asplenia or functional asplenia (including sickle cell disease)
- Complement deficiencies
- Elderly patients
- Young children (particularly <2 years for invasive disease) 8
These patients should receive parenteral third-generation cephalosporins empirically for any suspected H. influenzae infection, given higher risk of invasive disease and complications including meningitis, cerebritis, and septic arthritis 9.